

Erkki Ruoslahti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8376312/publications.pdf>

Version: 2024-02-01

72
papers

12,380
citations

41344

49
h-index

79698

73
g-index

77
all docs

77
docs citations

77
times ranked

13887
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular ZIP codes in targeted drug delivery. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	7
2	Silver Nanocarriers Targeted with a CendR Peptide Potentiate the Cytotoxic Activity of an Anticancer Drug. Advanced Therapeutics, 2021, 4, 2000097.	3.2	9
3	iRGD-Liposomes Enhance Tumor Delivery and Therapeutic Efficacy of Antisense Oligonucleotide Drugs against Primary Prostate Cancer and Bone Metastasis. Advanced Functional Materials, 2021, 31, 2100478.	14.9	32
4	Systemic brain tumor delivery of synthetic protein nanoparticles for glioblastoma therapy. Nature Communications, 2020, 11, 5687.	12.8	142
5	Generation of a multi-functional, target organ-specific, anti-fibrotic molecule by molecular engineering of the extracellular matrix protein, decorin. British Journal of Pharmacology, 2019, 176, 16-25.	5.4	39
6	Peptide-guided nanoparticles for glioblastoma targeting. Journal of Controlled Release, 2019, 308, 109-118.	9.9	60
7	Securing the Payload, Finding the Cell, and Avoiding the Endosome: Peptide-Targeted, Fusogenic Porous Silicon Nanoparticles for Delivery of siRNA. Advanced Materials, 2019, 31, e1902952.	21.0	73
8	Tumor-Targeting, MicroRNA-Silencing Porous Silicon Nanoparticles for Ovarian Cancer Therapy. ACS Applied Materials & Interfaces, 2019, 11, 23926-23937.	8.0	59
9	Tumor-specific macrophage targeting through recognition of retinoid X receptor beta. Journal of Controlled Release, 2019, 301, 42-53.	9.9	36
10	Immune-mediated ECM depletion improves tumour perfusion and payload delivery. EMBO Molecular Medicine, 2019, 11, e10923.	6.9	23
11	iRGD in combination with IL-2 reprograms tumor immunosuppression.. Journal of Clinical Oncology, 2019, 37, 55-55.	1.6	2
12	Antibiotic-loaded nanoparticles targeted to the site of infection enhance antibacterial efficacy. Nature Biomedical Engineering, 2018, 2, 95-103.	22.5	278
13	Immunogene therapy with fusogenic nanoparticles modulates macrophage response to Staphylococcus aureus. Nature Communications, 2018, 9, 1969.	12.8	132
14	Tracking the Fate of Porous Silicon Nanoparticles Delivering a Peptide Payload by Intrinsic Photoluminescence Lifetime. Advanced Materials, 2018, 30, e1802878.	21.0	35
15	Tumor penetrating peptides for improved drug delivery. Advanced Drug Delivery Reviews, 2017, 110-111, 3-12.	13.7	322
16	Tumor-Penetrating Nanosystem Strongly Suppresses Breast Tumor Growth. Nano Letters, 2017, 17, 1356-1364.	9.1	79
17	Targeting of p32 in peritoneal carcinomatosis with intraperitoneal linTT1 peptide-guided pro-apoptotic nanoparticles. Journal of Controlled Release, 2017, 260, 142-153.	9.9	57
18	Vascular changes in tumors resistant to a vascular disrupting nanoparticle treatment. Journal of Controlled Release, 2017, 268, 49-56.	9.9	7

#	ARTICLE	IF	CITATIONS
19	New Insights into "Permeability" as in the Enhanced Permeability and Retention Effect of Cancer Nanotherapeutics. ACS Nano, 2017, 11, 9567-9569.	14.6	199
20	Silicon Nanoparticles: Porous Silicon Nanoparticle Delivery of Tandem Peptide Anti-infectives for the Treatment of <i>Pseudomonas aeruginosa</i> Lung Infections (Adv. Mater. 35/2017). Advanced Materials, 2017, 29, .	21.0	2
21	In vivo cation exchange in quantum dots for tumor-specific imaging. Nature Communications, 2017, 8, 343.	12.8	56
22	Porous Silicon Nanoparticle Delivery of Tandem Peptide Anti-infectives for the Treatment of <i>Pseudomonas aeruginosa</i> Lung Infections. Advanced Materials, 2017, 29, 1701527.	21.0	82
23	Precision Targeting of Tumor Macrophages with a CD206 Binding Peptide. Scientific Reports, 2017, 7, 14655.	3.3	125
24	Identification of a peptide recognizing cerebrovascular changes in mouse models of Alzheimer's disease. Nature Communications, 2017, 8, 1403.	12.8	54
25	Selective Targeting of a Novel Vasodilator to the Uterine Vasculature to Treat Impaired Uteroplacental Perfusion in Pregnancy. Theranostics, 2017, 7, 3715-3731.	10.0	76
26	Paclitaxel-Loaded Polymersomes for Enhanced Intraperitoneal Chemotherapy. Molecular Cancer Therapeutics, 2016, 15, 670-679.	4.1	68
27	Urokinase-controlled tumor penetrating peptide. Journal of Controlled Release, 2016, 232, 188-195.	9.9	46
28	Plaque-penetrating peptide inhibits development of hypoxic atherosclerotic plaque. Journal of Controlled Release, 2016, 238, 212-220.	9.9	19
29	Tumor-homing peptides as tools for targeted delivery of payloads to the placenta. Science Advances, 2016, 2, e1600349.	10.3	119
30	iRGD peptide conjugation potentiates intraperitoneal tumor delivery of paclitaxel with polymersomes. Biomaterials, 2016, 104, 247-257.	11.4	123
31	Self-Sealing Porous Silicon-Calcium Silicate Core-Shell Nanoparticles for Targeted siRNA Delivery to the Injured Brain. Advanced Materials, 2016, 28, 7962-7969.	21.0	123
32	A peptide for targeted, systemic delivery of imaging and therapeutic compounds into acute brain injuries. Nature Communications, 2016, 7, 11980.	12.8	138
33	Composite Porous Silicon-Silver Nanoparticles as Theranostic Antibacterial Agents. ACS Applied Materials & Interfaces, 2016, 8, 30449-30457.	8.0	70
34	New p32/gC1qR Ligands for Targeted Tumor Drug Delivery. ChemBioChem, 2016, 17, 570-575.	2.6	75
35	Targeted silver nanoparticles for ratiometric cell phenotyping. Nanoscale, 2016, 8, 9096-9101.	5.6	33
36	Synthesis of linear and cyclic peptide-PEG-lipids for stabilization and targeting of cationic liposome-DNA complexes. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 1618-1623.	2.2	32

#	ARTICLE	IF	CITATIONS
37	Increasing Tumor Accessibility with Conjugatable Disulfide-Bridged Tumor-Penetrating Peptides for Cancer Diagnosis and Treatment. <i>Breast Cancer: Basic and Clinical Research</i> , 2015, 9s2, BCBCR.S29426.	1.1	3
38	Gated Luminescence Imaging of Silicon Nanoparticles. <i>ACS Nano</i> , 2015, 9, 6233-6241.	14.6	114
39	A tumor-penetrating peptide enhances circulation-independent targeting of peritoneal carcinomatosis. <i>Journal of Controlled Release</i> , 2015, 212, 59-69.	9.9	62
40	Nanoparticles coated with the tumor-penetrating peptide iRGD reduce experimental breast cancer metastasis in the brain. <i>Journal of Molecular Medicine</i> , 2015, 93, 991-1001.	3.9	73
41	Selection strategies for anticancer antibody discovery: searching off the beaten path. <i>Trends in Biotechnology</i> , 2015, 33, 292-301.	9.3	29
42	Neuropilin-1 and heparan sulfate proteoglycans cooperate in cellular uptake of nanoparticles functionalized by cationic cell-penetrating peptides. <i>Science Advances</i> , 2015, 1, e1500821.	10.3	68
43	Tumor-Penetrating iRGD Peptide Inhibits Metastasis. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 120-128.	4.1	99
44	Reprogramming Human Retinal Pigmented Epithelial Cells to Neurons Using Recombinant Proteins. <i>Stem Cells Translational Medicine</i> , 2014, 3, 1526-1534.	3.3	31
45	A free cysteine prolongs the half-life of a homing peptide and improves its tumor-penetrating activity. <i>Journal of Controlled Release</i> , 2014, 175, 48-53.	9.9	56
46	Clot-Targeted Micellar Formulation Improves Anticoagulation Efficacy of Bivalirudin. <i>ACS Nano</i> , 2014, 8, 10139-10149.	14.6	14
47	An endocytosis pathway initiated through neuropilin-1 and regulated by nutrient availability. <i>Nature Communications</i> , 2014, 5, 4904.	12.8	156
48	A Novel Vascular Homing Peptide Strategy to Selectively Enhance Pulmonary Drug Efficacy in Pulmonary Arterial Hypertension. <i>American Journal of Pathology</i> , 2014, 184, 369-375.	3.8	46
49	Etchable plasmonic nanoparticle probes to image and quantify cellular internalization. <i>Nature Materials</i> , 2014, 13, 904-911.	27.5	156
50	Quantity and accessibility for specific targeting of receptors in tumours. <i>Scientific Reports</i> , 2014, 4, 5232.	3.3	33
51	DEPLETION OF TUMOR-ASSOCIATED MACROPHAGES WITH CLODRONATE-LOADED PLGA NANOPARTICLES. <i>Nano LIFE</i> , 2013, 03, 1343005.	0.9	1
52	Proapoptotic Peptide-Mediated Cancer Therapy Targeted to Cell Surface p32. <i>Molecular Therapy</i> , 2013, 21, 2195-2204.	8.2	74
53	Targeted Antiscarring Therapy for Tissue Injuries. <i>Advances in Wound Care</i> , 2013, 2, 50-54.	5.1	34
54	Peptides as Targeting Elements and Tissue Penetration Devices for Nanoparticles. <i>Advanced Materials</i> , 2012, 24, 3747-3756.	21.0	353

#	ARTICLE	IF	CITATIONS
55	Targeted nanoparticle enhanced proapoptotic peptide as potential therapy for glioblastoma. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 17450-17455.	7.1	320
56	Drug delivery: Magnetic Luminescent Porous Silicon Microparticles for Localized Delivery of Molecular Drug Payloads (Small 22/2010). Small, 2010, 6, 2545-2545.	10.0	0
57	Nanoparticle-induced vascular blockade in human prostate cancer. Blood, 2010, 116, 2847-2856.	1.4	149
58	Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs. Science, 2010, 328, 1031-1035.	12.6	926
59	Targeting of drugs and nanoparticles to tumors. Journal of Cell Biology, 2010, 188, 759-768.	5.2	770
60	C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 16157-16162.	7.1	674
61	Tissue-Penetrating Delivery of Compounds and Nanoparticles into Tumors. Cancer Cell, 2009, 16, 510-520.	16.8	967
62	Systematic Surface Engineering of Magnetic Nanoworms for In vivo Tumor Targeting. Small, 2009, 5, 694-700.	10.0	263
63	Targeting of albumin-embedded paclitaxel nanoparticles to tumors. Nanomedicine: Nanotechnology, Biology, and Medicine, 2009, 5, 73-82.	3.3	202
64	Magnetic Iron Oxide Nanoworms for Tumor Targeting and Imaging. Advanced Materials, 2008, 20, 1630-1635.	21.0	516
65	Mitochondrial/Cell-Surface Protein p32/gC1qR as a Molecular Target in Tumor Cells and Tumor Stroma. Cancer Research, 2008, 68, 7210-7218.	0.9	308
66	Biomimetic amplification of nanoparticle homing to tumors. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 932-936.	7.1	434
67	Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 9381-9386.	7.1	259
68	Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. Cancer Cell, 2003, 4, 393-403.	16.8	232
69	Targeting the prostate for destruction through a vascular address. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 1527-1531.	7.1	282
70	A tumor-homing peptide with a targeting specificity related to lymphatic vessels. Nature Medicine, 2002, 8, 751-755.	30.7	447
71	Anti-cancer activity of targeted pro-apoptotic peptides. Nature Medicine, 1999, 5, 1032-1038.	30.7	866
72	Isolation of High-Affinity Peptide Antagonists of 14-3-3 Proteins by Phage Display. Biochemistry, 1999, 38, 12499-12504.	2.5	279